Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs

BACKGROUND: Geographic variation in the use of prescription drugs, particularly those deemed harmful by the FDA, may lead to variation in patient exposure to adverse drug events. One such drug is the glucose-lowering drug rosiglitazone, for which the FDA issued a safety alert on May 21, 2007, follow...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Manag Care Spec Pharm
Hlavní autoři: Ahuja, Vishal, Sohn, Min-Woong, Birge, John R., Syverson, Chad, Budiman-Mak, Elly, Emanuele, Nicholas, Cooper, Jennifer M., Huang, Elbert S.
Médium: Artigo
Jazyk:Inglês
Vydáno: Academy of Managed Care Pharmacy 2015
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4861222/
https://ncbi.nlm.nih.gov/pubmed/26679970
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18553/jmcp.2015.21.12.1214
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky